Results 41 to 50 of about 6,964 (243)

Pharmacogenetics of thiopurine therapy: from thiopurine S-methyltransferase to S-adenosylmethionine [PDF]

open access: yesBMC Pharmacology, 2009
Background The efficiency and safety of the thiopurine therapy rely on the concentration of patient’s cytotoxic thioguanine nucleotides (TGN), which in turn depend on the deactivation of thiopurine drugs by thiopurine S-methyltransferase (TPMT). The activity of TPMT largely depends on the presence of genetic polymorphisms. Determination of mutations in
Mlinarič-Raščan, Irena   +2 more
openaire   +1 more source

Thiopurine methyltransferase phenotypes and genotypes in Brazilians [PDF]

open access: yesPharmacogenetics, 2003
The polymorphism of thiopurine methyltransferase (TPMT) was studied in 306 healthy Brazilians who were classed, on the basis of self-declared colour and ancestry, as Euro-derived (n = 81), Afro-derived (n = 18) or having interethnic admixture (n = 204).
Marcelo, Reis   +2 more
openaire   +2 more sources

Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID) [PDF]

open access: yesIntestinal Research, 2015
Background/AimsFor decades, thiopurines have been the mainstay of inflammatory bowel disease (IBD) treatment and will play an important role in the future.
Kang-Moon Lee   +5 more
doaj   +1 more source

Band 3/anion exchanger 1/solute carrier family 4 member 1 expression as determinant of cellular sensitivity to selenite exposure

open access: yesBiochemistry and Biophysics Reports, 2022
Selenium is a chalcogen element that is essential in animals, but is highly toxic when ingested above the nutritional requirement. Selenite is used as a supplement in patients receiving total parenteral nutrition. However, the therapeutic and toxic doses
Yasunori Fukumoto   +4 more
doaj   +1 more source

Recent advances in the pharmacogenomics of thiopurine methyltransferase [PDF]

open access: yesThe Pharmacogenomics Journal, 2001
The thiopurine drugs (6-mercaptopurine, 6-thioguanine and azathioprine) are commonly used cytotoxic agents and immunosuppressants. One important route for the metabolism of these agents is methylation, mediated by thiopurine methyltransferase (TPMT). It is now well established that inter-individual variation in sensitivity to thiopurines can be due to ...
Coulthard SA, Hall AG
openaire   +2 more sources

Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

open access: yesFrontiers in Medicine, 2021
Thiopurines have been a cornerstone in the treatment of inflammatory bowel disease (IBD). Although they have been used for more than 50 years, there are still some unsolved issues about their efficacy and, also, some safety concerns, mainly the risk of ...
Carla J. Gargallo-Puyuelo   +5 more
doaj   +1 more source

Thiopurine Methyltransferase Enzyme Activity Determination before Treatment of Inflammatory Bowel Disease with Azathioprine: Effect on Cost and Adverse Events

open access: yesCanadian Journal of Gastroenterology, 2005
BACKGROUND: Azathioprine (AZA), used to treat inflammatory bowel disease (IBD), is metabolized by thiopurine methyltransferase (TPMT). The accumulation of individual metabolites varies because humans display genetic polymorphism for TPMT expression ...
Farzana A Sayani   +4 more
doaj   +1 more source

Role of Oxidative Stress Mediated by Glutathione-S-transferase in Thiopurines' Toxic Effects [PDF]

open access: yes, 2015
Azathioprine (AZA), 6-mercaptopurine (6-MP), and 6-thioguanine (6-TG) are antimetabolite drugs, widely used as immunosuppressants and anticancer agents.
De Iudicibus, Sara   +9 more
core   +1 more source

Expression of thiopurine methyltransferase in South Asians [PDF]

open access: yesGut, 2003
Azathioprine and its metabolite 6-mercaptopurine (6-MP) are widely used in the treatment of Crohn’s disease, ulcerative colitis, autoimmune hepatitis, and a range of other inflammatory and autoimmune diseases, as well as for prevention of transplant rejection.
E, Tsironi   +3 more
openaire   +2 more sources

6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients [PDF]

open access: yes, 2017
Background and Aim: Thiopurines have a favorable benefit–risk ratio in the treatment of inflammatory bowel disease. A feared adverse event of thiopurine therapy is myelotoxicity, mostly occurring due to toxic concentrations of the pharmacologically ...
Bodegraven, A.A. (Ad) van   +9 more
core   +3 more sources

Home - About - Disclaimer - Privacy